Background: Trapeziometacarpal (TMC) osteoarthritis is a degenerative disease of the thumb’s first carpometacarpal joint. Although several treatments can relieve symptoms, none clearly promote cartilage repair or modify disease progression. Regenerative therapies using adipose tissue have recently emerged as a and possible cartilage restoration promissing treatment. Methods: A case series of 45 patients (63 joints) treated at Image Regenerative Clinic between January 2018 and December 2022 was analyzed. Patients (aged 41–77 years) underwent ultrasound- guided intra-articular transplantation of microfragmented adipose tissue (MFAT, Lipogems®). Outcomes were assessed pre-treatment and at 6 and 12 months with the Disabilities of the Arm, Shoulder and Hand (DASH) score and Visual Analog Scale (VAS). Patient satisfaction was graded on a 4-point scale (1 = poor; 4 = excellent). Results: At 6 months, satisfaction ratings were poor (9/45), fair (31/45), good (4/45), and excellent (1/45). At 12 months, ratings improved to poor (8/45), fair (12/45), good (18/45), and excellent (7/45). VAS scores for the most symptomatic joint fell from 5.3 to 2.2 (Δ 3.1 points). Thirty-four of 45 patients showed ≥ 30-point DASH improvement. No patient required surgery within 12 months; eight patients with poor outcomes had surgery in the following year. Discussion: the best results were observed in Eaton stages II and III, where joint structures still retain regenerative potential. In more advanced stage IV cases, clinical improvement was often temporary, although many patients still reported meaningful pain relief and functional recovery for several months—making MFAT a valuable bridge therapy that can postpone or reduce the need for surgery. Conclusions: MFAT transplantation was safe, minimally invasive, and clinically effective in most patients, representing a valuable early or intermediate option for TMC osteoarthritis.